



**Name** Min-Chi Lu, MD, PhD

**Current Positions** Professor and Chairman of Microbiology & Immunology, and Professor of Medicine, School of Medicine, China Medical University; Attending Physician, Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

**Telephone** +886-42205-3366 ext. 2167  
**E-mail** luminchi@mail.cmu.edu.tw  
**E-Portfolio Website**  
**Personal Website**

#### Education

1996 - 1997 Postdoctoral Research Associate, Department of Microbiology and Cell and Molecular Biology Program, Michigan State University, MI, U.S.  
 1991 - 1996 Ph.D., Department of Physiology, Michigan State University, MI, U.S.  
 1982 - 1989 M.D., China Medical University School of Medicine, Taichung, Taiwan

#### Academic and Hospital Appointments

2010 - 2016 Professor of Medicine, and Microbiology and Immunology, Chung Shan Medical University School of Medicine, Taichung, Taiwan.  
 2008 - 2016 Chief, Division of Infectious Diseases, Department of Internal Medicine; Director, Infection Control Team, Chung Shan Medical University Hospital, Taichung, Taiwan  
 2003 - 2016 Attending Physician, Division of Infectious Diseases, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan  
 2004 - 2008 Superintendent, Chung Shan Medical University Chung-Kang Hospital, Taichung, Taiwan  
 2003 - 2009 Associate Professor of Medicine, and Microbiology and Immunology, Chung Shan Medical University School of Medicine, Taichung, Taiwan.

#### Research Interests

Dr. Lu has research interests in the fields of clinical infectious diseases, bacterial pathogenesis, the spread of multidrug resistant pathogens, infection prevention and control measures, and antimicrobial stewardship.

#### Selected Grants:

1. The study of ST11 *Klebsiella pneumoniae* and drug-resistance plasmids association: Phylogenomic analysis and the development of novel antimicrobials. (PI: 109-2314-B-039 -049 -MY3; 8/1/2020 ~ 7/31/2023)
2. Bacteremic isolates of carbapenem-resistant *Klebsiella pneumoniae*: a genomic epidemiology and virulence study. (PI: 108-2314-B-039-026-; 8/1/2019 ~ 7/31/2020)

#### Selected Publications

1. Hsieh WH, Cheng MY, Ho MW, Chou CH, Lin PC, Chi CY, Liao WC, Chen CY, Leong LY, Tien N, Lai HC, Lai YC\*\*, [Lu MC\\*](#). Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan. J Microbiol Immunol Infect. 2020; 53(3):459-466.

2. Chen WC, Lai YC, Lin CH, Zheng JF, Hung WC, Wang YJ, Kuo TH, Wu LH, Tong YS, [Lu MC\\*](#), Liu KS\*\*. First COVID-19 mortality case in Taiwan with bacterial co-infection by national surveillance of critically ill patients with influenza-negative pneumonia. *J Microbiol Immunol Infect.* 2020;53(4):652-6.
3. [Lu MC](#), Chen YT, Tang HL, Liu YY, Chen BH, Wang YW, Chen YS, Teng RH, Hong YP, Chiou CS, Chiang MK, Lai YC. Transmission and evolution of OXA-48-producing *Klebsiella pneumoniae* ST11 in a single hospital in Taiwan. *J Antimicrob Chemother.* 2020;75(2):318-326.
4. Lee YL, [Lu MC](#), Shao PL, Lu PL, Chen YH, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Liao MH, Hsueh PR\*. Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018. *Int J Antimicrob Agents.* 2019 Sep;54(3):318-328.
5. Liu JW, Chen YH, Lee WS, Lin JC, Huang CT, Lin HH, Liu YC, Chuang YC, Tang HJ, Chen YS, Ko WC, [Lu MC](#), Wang FD. Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia. *Antimicrob Agents Chemother.* 2019 Jul 25;63(8). pii: e00023-19. doi: 10.1128/AAC.00023-19.
6. Lai YC, [Lu MC](#), Hsueh PR\*. Hypervirulence and carbapenem resistance: two distinct evolutionary directions that led high-risk *Klebsiella pneumoniae* clones to epidemic success. *Expert Rev Mol Diagn.* 2019 Sep;19(9):825-837. doi: 10.1080/14737159.2019.1649145. Epub 2019 Aug 1.
7. Li YT, Wang YC, Lee HL, Tsao SC, [Lu MC\\*](#), Yang SF\*. Monocyte Chemoattractant Protein-1, a Possible Biomarker of Multiorgan Failure and Mortality in Ventilator-Associated Pneumonia. *Int J Mol Sci.* 2019 May 6;20(9). pii: E2218. doi: 10.3390/ijms20092218.
8. Wang YC, Tang HL, Liao YC, Chiou CS, Chen YT, Chiang MK, [Lu MC\\*](#), Lai YC\*. Cocarriage of Distinct bla KPC-2 and bla OXA-48 Plasmids in a Single Sequence Type 11 Carbapenem-Resistant *Klebsiella pneumoniae* Isolate. *Antimicrob Agents Chemother.* 2019 May 24;63(6). pii: e02282-18. doi: 10.1128/AAC.02282-18.
9. Jean SS, Lee NY, Tang HJ, [Lu MC](#), Ko WC, Hsueh PR\*. Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects. *Front Microbiol.* 2018 Nov 27;9:2888. doi: 10.3389/fmicb.2018.02888. eCollection 2018.
10. Lai CC, Lin YT, Lin YT, [Lu MC](#), Shi ZY, Chen YS, Wang LS, Tseng SH, Lin CN, Chen YH, Ko WC, Wang FD\*, Hsueh PR, Infection Control Society of Taiwan. Clinical characteristics of patients with bacteraemia due to the emergence of mcr-1-harboring Enterobacteriaceae in humans and pigs in Taiwan. *Int J Antimicrob Agents.* 2018;52(5):651-657.
11. [Lu MC](#), Tang HL, Chiou CS, Wang YC, Chiang MK, Lai YC\*. Clonal dissemination of carbapenemase-producing *Klebsiella pneumoniae*: Two distinct sub-lineages of Sequence Type 11 carrying blaKPC-2 and blaOXA-48. *Int J Antimicrob Agents.* 2018;52(5):658-662.